German pharmaceutical company Evertz Pharma GmbH has made a groundbreaking move by allocating 100 bitcoins (BTC) to its treasury reserves. This strategic decision marks the first instance of a German company adopting a dedicated Bitcoin reserve. This underscores its confidence in the cryptocurrency’s long-term value and stability.
Building on its Bitcoin strategy initiated in 2020, Evertz Pharma is diversifying its financial holdings and embracing Bitcoin as a store of value, setting a notable precedent in the industry.
Evertz Pharma Boosts Its Bitcoin Treasury
As a privately held German company, Evertz Pharma differs from public BTC adopters like Strategy and Metaplanet, offering a unique perspective on cryptocurrency investment as a private enterprise.
The company’s BTC treasury, initiated in December 2020 with a $2.3 million (€2 million) purchase, continues to grow as the company regularly allocates profits to Bitcoin. This strategic reserve aims to ensure long-term stability,
Reflecting the firm’s confidence in digital assets as a complement to traditional financial holdings, the company added 100 BTC to its reserves in May 2025, valued at $10.8 million. Managing Director Dominik Evertz sees the leading crypto as a globally tradable, scarce asset that boosts financial stability. He believes it complements the company’s reserves, aligning with its future-focused strategy and enhancing long-term financial security through diversification and strategic investment in digital assets.
Evertz Pharma’s decision to add bitcoin to its treasury likely stems from several key factors. The cryptocurrency’s decentralized nature and limited supply provide a hedge against inflation and currency devaluation. Increasing institutional acceptance and regulatory recognition enhances its credibility and security. Moreover, bitcoin’s potential for long-term value appreciation renders it an appealing addition to an investment portfolio.
A Growing Trend
Evertz Pharma’s significant bitcoin holdings signal a bold shift for a healthcare-focused company, as they follow in the footsteps of Semler Scientific, which began its Bitcoin acquisition last year.
Semler Scientific acquired 581 BTC worth $40 million, designating bitcoin as its primary treasury reserve asset. Chairman Eric Semler believes the apex coin is a reliable store of value and a growth asset. In his opinion, he cited its structural resilience and potential for substantial returns, which are superior to those of gold.
As a private company, Evertz Pharma draws key lessons from these models, adapting them to fit its unique context as a German family-owned business.
